Cytosorbents Corp (CTSO) stock
CTSONasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$4.87−0.50 (-9.31%)
Close on Nov 13, 2026Market cap $306.04MP/E –Yield –
Cytosorbents r&d expenses
Research and development expenses are spending on new products and technology.
Cytosorbents's R&D Expenses for the twelve months ending Sep 30, 2024 was $9.72M, down 35.4% year over year. For fiscal 2023 it was $15.73M, up 4.0% from the year before. Over ten years it grew 24.6% a year on average. The highest annual figure on record is $16.38M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $15.73M | +4.0% |
| FY2022 | Dec 31, 2022 | $15.12M | -7.7% |
| FY2021 | Dec 31, 2021 | $16.38M | +85.9% |
| FY2020 | Dec 31, 2020 | $8.81M | -27.1% |
| FY2019 | Dec 31, 2019 | $12.09M | +56.6% |
| FY2018 | Dec 31, 2018 | $7.72M | +139.8% |
| FY2017 | Dec 31, 2017 | $3.22M | -20.9% |
| FY2016 | Dec 31, 2016 | $4.07M | +5.2% |
| FY2015 | Dec 31, 2015 | $3.87M | +59.2% |
| FY2014 | Dec 31, 2014 | $2.43M | +39.8% |
| FY2013 | Dec 31, 2013 | $1.74M | -31.3% |
| FY2012 | Dec 31, 2012 | $2.53M | -12.3% |
| FY2011 | Dec 31, 2011 | $2.89M | +64.4% |
| FY2010 | Dec 31, 2010 | $1.76M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.45M | -21.5% |
| Q1 FY2026 | Mar 31, 2026 | $1.03M | -32.5% |
| Q2 FY2025 | Jun 30, 2025 | $1.26M | -43.9% |
| Q1 FY2025 | Mar 31, 2025 | $1.66M | -59.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.85M | -50.6% |
| Q2 FY2024 | Jun 30, 2024 | $1.52M | -58.6% |
| Q1 FY2024 | Mar 31, 2024 | $2.25M | -46.7% |
| Q4 FY2023 | Dec 31, 2023 | $4.10M | +20.4% |
| Q3 FY2023 | Sep 30, 2023 | $3.75M | +14.0% |
| Q2 FY2023 | Jun 30, 2023 | $3.67M | -12.3% |
| Q1 FY2023 | Mar 31, 2023 | $4.21M | -0.7% |
| Q4 FY2022 | Dec 31, 2022 | $3.40M | -44.6% |
| Q3 FY2022 | Sep 30, 2022 | $3.29M | -22.8% |
| Q2 FY2022 | Jun 30, 2022 | $4.18M | +13.1% |
| Q1 FY2022 | Mar 31, 2022 | $4.24M | +85.9% |
| Q4 FY2021 | Dec 31, 2021 | $6.14M | +128.5% |
| Q3 FY2021 | Sep 30, 2021 | $4.26M | +143.1% |
| Q2 FY2021 | Jun 30, 2021 | $3.70M | +53.8% |
| Q1 FY2021 | Mar 31, 2021 | $2.28M | +16.1% |
| Q4 FY2020 | Dec 31, 2020 | $2.69M | -24.5% |
| Q3 FY2020 | Sep 30, 2020 | $1.75M | -44.9% |
| Q2 FY2020 | Jun 30, 2020 | $2.41M | -17.9% |
| Q1 FY2020 | Mar 31, 2020 | $1.97M | -18.7% |
| Q4 FY2019 | Dec 31, 2019 | $3.56M | +46.8% |
| Q3 FY2019 | Sep 30, 2019 | $3.19M | +63.9% |
| Q2 FY2019 | Jun 30, 2019 | $2.93M | +85.9% |
| Q1 FY2019 | Mar 31, 2019 | $2.42M | +40.2% |
| Q4 FY2018 | Dec 31, 2018 | $2.42M | +45.5% |
| Q3 FY2018 | Sep 30, 2018 | $1.94M | +202.2% |
| Q2 FY2018 | Jun 30, 2018 | $1.58M | +244.0% |
| Q1 FY2018 | Mar 31, 2018 | $1.73M | +267.4% |
| Q4 FY2017 | Dec 31, 2017 | $1.67M | +74.8% |
| Q3 FY2017 | Sep 30, 2017 | $643.19K | -45.1% |
| Q2 FY2017 | Jun 30, 2017 | $458.03K | – |
| Q1 FY2017 | Mar 31, 2017 | $469.55K | – |
| Q4 FY2016 | Dec 31, 2016 | $952.75K | – |
| Q3 FY2016 | Sep 30, 2016 | $1.17M | – |
See a number that looks wrong?